Juncture Wealth Strategies LLC Makes New Investment in Abbott Laboratories $ABT

Juncture Wealth Strategies LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 6,658 shares of the healthcare product maker’s stock, valued at approximately $658,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. boosted its position in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp raised its holdings in shares of Abbott Laboratories by 1.7% in the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock worth $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. J. Stern & Co. LLP lifted its stake in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Abbott Laboratories by 0.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock worth $2,241,076,000 after buying an additional 118,014 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Abbott Laboratories in the second quarter worth approximately $1,603,607,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 2.0%

NYSE:ABT traded down $1.96 during trading hours on Tuesday, hitting $98.14. 10,575,706 shares of the stock traded hands, compared to its average volume of 11,348,987. The firm has a 50 day moving average price of $106.89 and a 200 day moving average price of $98.52. The firm has a market cap of $169.82 billion, a price-to-earnings ratio of 31.76, a PEG ratio of 1.81 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.13. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is 81.55%.

Analyst Ratings Changes

A number of brokerages have recently commented on ABT. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price on the stock. BTIG Research upped their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. TD Cowen reiterated a “buy” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $119.80.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.